Table 2. Summary of some of the included studies.

COX-2, cyclooxygenase-2; NSAIDs, nonsteroidal anti-inflammatory drugs; UC, ulcerative colitis; NOSH-aspirin, nitric oxide and H2S releasing aspirin; NF-kB, nuclear factor of Kappa light chain enhancer of B cells 

Author/year	Type of study	Purpose of the study	Results/conclusion
Ullman and Itzkowitz, 2011	Clinical review [12]	Intestinal inflammation and cancer	Patients with UC and Crohn's disease believed to have increased risk of colon cancer as chronic inflammation promotes carcinogenesis
Tsioulias et al., 2015	RCT [11]	NSAIDs and colorectal cancer control: promise and challenges	Some people are eligible to be a candidate for chemoprevention with NSAIDs
Mohammed et al., 2018	Clinical review [9]	Clinically relevant anti-inflammatory agents for chemoprevention of colorectal cancer: new perspectives	Number of drugs have to be studied to use for chemoprevention as NSAIDs but still need more studies to reduce the side effect of the use
Chen and Stark, 2017	Clinical review [10]	Aspirin prevention of colorectal cancer: focus on NF-κB signaling and the nucleolus	Aspirin and related NSAIDs have anti-tumor activity and the potential to prevent cancer, particularly colorectal cancer
Dovizio et al., 2012	Clinical review [13]	Mechanistic and pharmacological issues of aspirin as an anticancer agent	Chemopreventive mechanism of aspirin thought to act through COX-2 inhibitory and COX-2 non-inhibitory and antiplatelet effects
Rodríguez et al., 2016	A systematic review [14]	Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies	The risks of significant bleeding with low-dose aspirin in real-world settings are of a similar magnitude to those reported in randomized trials
Kodela et al., 2015	Clinical review [15]	NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemopreventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications	NOSH-aspirin (NBS-1120), a novel hybrid that releases nitric oxide and hydrogen sulfide, was designed to be a safer alternative for aspirin In chemoprevention